Mirtazapine-maprotiline

From Psychiatrienet
Revision as of 10:44, 14 October 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine
Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline

Switch medication from mirtazapine to maprotiline.[1] [2]

Nietinrijdenbord.png Stop mirtazapine
  • Before day 1: Gradually reduce dosage of mirtazapine to a maximum of 30 mg/day, when this dosage is > 30 mg/day.
  • Day 1: Reduce dosage of mirtazapine to 15 mg/day.
  • Day 8: Stop administration of mirtazapine.
Eenrichtingbord.png Start maprotiline
  • Day 2: Start with normal dosage and increase with about 25% (up to 50%) every 3 days to target dose.
  • Start administration of maprotiline in a dosage of 25-75 mg/day.
Infobord.png More information
  • No wash-out period is needed.
  • "Start low, go slow" is not required, but caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.